Table 4. Univariate and multivariate analysis for relapse-free survival in node metastasis-free patients (Cox proportional hazards model).
| Variable |
Value | n | Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | ||||
| Age at operation | (ref = < 50) | 50 < | 344 | 0.41 | 0.15-1.11 | 0.08 | |||
| Menopause state | (ref = Pre) | Post | 342 | 0.67 | 0.24-1.97 | 0.44 | |||
| T stage | (ref = T1) | T2 < | 343 | 2.02 | 0.74-5.52 | 0.16 | |||
| Histopathology | (ref = Lobular) | Ductal | 312 | 0.26 | 0.05-4.95 | 0.29 | |||
| Nuclear Grade | (ref = 1,2) | 3 | 340 | 6.04 | 2.16-17.2 | 0.0009* | 5.50 | 1.96-15.7 | 0.0016* |
| ERα (IHC) | (ref = <1%) | 1% < | 344 | 0.49 | 0.18-1.59 | 0.22 | |||
| PgR (IHC) | (ref = <1%) | 1% < | 342 | 0.52 | 0.19-1.48 | 0.21 | |||
| HER2 | (ref = Negative) | Positive | 344 | 1.41 | 0.32-4.41 | 0.60 | |||
| Ki67 (MIB1) | (ref = < 15%) | 15 < | 327 | 2.24 | 0.76-8.13 | 0.14 | |||
| AR | (ref = <1%) | 1% < | 338 | 0.44 | 0.15-1.61 | 0.19 | |||
| ERβ | (ref = the 25th percentile) | Positive | 295 | 0.70 | 0.23-2.39 | 0.55 | |||
| PA1 in the nucleus | (ref = the 25th percentile) | Positive | 344 | 0.34 | 0.12-0.93 | 0.0374* | 0.34 | 0.12-0.97 | 0.045* |
| PA1 in the cytoplasm | (ref = the 25th percentile) | Positive | 344 | 0.82 | 0.29-2.21 | 0.69 | |||
| Systemic therapy | (ref = No) | Yes | 340 | 0.94 | 0.25-6.06 | 0.93 | |||
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor; HR, Hazard Ratio; CI, Confidence Interval; NS, Not significant.
Considering the co-effect of PA1 expression with each factor was used in the multivariate analysis, respectively
* Factor showing statistical significance.